Who Gets Prescribed Peptides: Six Months of Telehealth Data From 2,500 Patients

Rx Peps Direct looked at every approved prescription order from its first patients in May 2026 through November 18, 2026: 2,506 patients. The median patient is 45, and only 7.5% are under 30. Six in ten have never ordered a weight-loss product, and men and women order markedly different peptides.

6 min read · Updated November 18, 2026

Marcus HansenBy Marcus HansenFounder & CEO, Rx Peps Direct
median age at first order
45
median age at first order
of patients are under 30
7.5%
of patients are under 30
have never ordered a weight-loss product
59.8%
have never ordered a weight-loss product

Key numbers

2,506 patients, May 13 to November 18, 2026. Each row can be linked on its own by adding its anchor to this page's address, for example #median-age.

Key numbers from Who Gets Prescribed Peptides: Six Months of Telehealth Data From 2,500 Patients, May 13 to November 18, 2026
FindingFigureOut of
Median age at first order452,506 patients
Patients aged 40 to 5958.2%1,458 of 2,506 patients
Patients aged 50 or older35.7%895 of 2,506 patients
Patients under 307.5%189 of 2,506 patients
Never ordered a weight-loss product59.8%1,498 of 2,506 patients (men 69.2%, women 46.5%)
Ordered a product containing BPC-157 or TB-50048.4%1,214 of 2,506 patients
Women and men42% / 58%1,045 women, 1,460 men
Women's share of GHK-Cu patients61.2%423 patients
Women's share of GLP-1 patients59.4%764 patients
Men's share of growth-hormone-releasing peptide patients76.2%719 patients
Had a second order approved, among patients whose first order was 60 or more days earlier65.2%733 of 1,124 patients

How old are peptide patients?

The median patient was 45 at their first order and the mean was 47.9. More than half (58.2%) were 40 to 59, more than a third (35.7%) were 50 or older, and only 7.5% were under 30. The 40s are the largest group, at 34.0% of patients.

Patients by age at first approved order
Age at first orderPatientsShare
18 to 291897.5%
30 to 3956922.7%
40 to 4985334.0%
50 to 5960524.1%
60 to 692188.7%
70 and older722.9%

The women skew older too: 69% of them (721 of 1,045) were 40 or older at their first order.

How many patients have ordered a weight-loss product?

About four in ten. The other 59.8% (1,498 of 2,506) have never had a weight-loss product approved: 69.2% of men and 46.5% of women.

Do men and women order different peptides?

Yes. Patients are 58% men and 42% women, but some product groups lean much further one way.

Share of each product group's patients by sex
Product groupPatientsWho orders it
Wolverine stack (BPC-157 and TB-500)36880.7% men
Growth-hormone-releasing peptides71976.2% men
NAD+ injection35952.1% women
GLP-1s (tirzepatide, semaglutide)76459.4% women
GHK-Cu, injectable and topical42361.2% women

The study records who orders what. It does not record why.

How many patients ordered BPC-157 or TB-500?

48.4% (1,214 of 2,506) ordered at least one product containing BPC-157 or TB-500, including the KLOW and Wolverine blends. Our most popular peptides analysis ranks the individual products.

Do patients come back?

Two in three do. Of the 1,124 patients whose first order was at least 60 days before November 18, 65.2% (733) have had a second order approved.

Methodology

A de-identified, aggregate analysis of approved prescription orders at one U.S. telehealth practice. Figures describe Rx Peps Direct patients only and are not a national estimate.

RecordsEvery approved prescription order at Rx Peps Direct from its first patients (May 13, 2026) through November 18, 2026.
PatientsCounted once each, matched by name and date of birth: 2,506 patients.
AgeAge at the patient's first approved order, from the date of birth entered at intake.
SexBiological sex as entered at intake: 1,460 men and 1,045 women. One patient who chose another answer is left out of the splits by sex.
ProductsGrouped from the product names on each approved order, across doses and forms.
PrivacyOnly aggregate counts were pulled. No individual patient can be identified from these figures, and the smallest group reported is 72 patients.

How the product groups are defined

Weight-loss productsTirzepatide, semaglutide, AOD-9604, 5-Amino-1MQ, tesofensine, the Lean Stacks and lipotropic (Lipo-B and Lipo-C) injections
GLP-1sTirzepatide and semaglutide, in every form
Growth-hormone-releasing peptidesCJC-1295/ipamorelin, tesamorelin, sermorelin and their ipamorelin combinations. The Lean Stacks are not counted here.
BPC-157 or TB-500Any product containing either: BPC-157, TB-500, KLOW and the Wolverine stack, in every form
GHK-CuInjectable GHK-Cu and the GHK-Cu creams, serums and hair solution

This study counts approved orders and matches patients by name and date of birth. Our earlier most popular peptides analysis counted every paid order and matched patients by email, so its figures differ slightly.

Limits

  • These are the patients of one telehealth practice, which prescribes in 28 states plus Washington, DC. They are not a national estimate of who uses peptides.
  • Only approved orders count. Orders a provider did not approve, and orders still under review, are left out.
  • Matching by name and date of birth can count one person twice if they entered their name two ways.
  • Age and sex are what patients entered at intake.
  • Patients can only order what Rx Peps Direct prescribes, so the product mix reflects its catalog.

How to cite this study

Rx Peps Direct, "Who Gets Prescribed Peptides: Six Months of Telehealth Data From 2,500 Patients," November 18, 2026, https://www.rxpepsdirect.com/learn/who-gets-prescribed-peptides-2026

Reporters may quote any figure on this page with that credit and a link to this page.

Media contact

Marcus Hansen, Founder and CEO, Rx Peps Direct: support@rxpepsdirect.com. The full de-identified breakdown is available on request.

Dr. Jonathan Snipes, Medical Director and co-founder of Rx Peps Direct, is available for clinical questions. Marcus Hansen answers questions about the data.

About Rx Peps Direct

Rx Peps Direct (RxPepsDirect.com) is a telehealth practice that provides prescriptions for pharmaceutical-grade compounded peptides in 28 states plus Washington, DC. Patients pay a single $39 medical review fee. Rx Peps Direct sends every prescription to a licensed U.S. 503A compounding pharmacy, which fills it and ships it directly to the patient, and the patient pays the pharmacy at its wholesale price. Rx Peps Direct prescribes only non-controlled peptides. Compounded medications are not FDA-approved.

Frequently asked questions

What is the average age of people prescribed peptides?
At Rx Peps Direct, the median patient was 45 at their first approved order and the mean was 47.9, across 2,506 patients from May 13 to November 18, 2026. 58.2% were 40 to 59, and only 7.5% were under 30.
Are most peptide patients taking weight-loss medication?
No. 59.8% of the 2,506 Rx Peps Direct patients in this study have never ordered a weight-loss product: 69.2% of men and 46.5% of women.
Do men and women order different peptides?
Yes. Women are 61.2% of Rx Peps Direct patients on GHK-Cu and 59.4% of those on GLP-1s. Men are 76.2% of patients on growth-hormone-releasing peptides and 80.7% of those on the Wolverine stack. NAD+ injections split about evenly.
How do I cite this study?
Cite it as: Rx Peps Direct, "Who Gets Prescribed Peptides: Six Months of Telehealth Data From 2,500 Patients," November 18, 2026, rxpepsdirect.com/learn/who-gets-prescribed-peptides-2026.